This bill establishes a new interagency committee to coordinate federal oversight of biotechnology products across multiple agencies, including the USDA, FDA, EPA, and NIH. The committee, chaired by the Director of the Office of Science and Technology Policy, will work to streamline regulatory timelines, align data requirements across agencies, reduce duplicative reviews, and establish clear points of contact for biotechnology developers navigating the approval process. Within 180 days of enactment, the committee must develop a unified process for determining whether biotech products could occur naturally or through conventional breeding, and must provide specific guidance on emerging biotechnology methods like molecular farming and precision fermentation. The bill requires the committee to submit annual reports to Congress detailing its progress, staffing needs, and any statutory barriers to efficient oversight, while the Government Accountability Office will review the committee's effectiveness and provide findings within two years. The legislation excludes human medical research and products regulated solely by the FDA from these coordination requirements.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.